“Following the recent approval of bimekizumab in Europe, we are very pleased to learn about the percentage of new two-year knowledge with EADV supporting the clinical price of bimekizumab in the remedy of moderate to severe psoriasis. The diversity of knowledge of efficacy and long-term protection presented gives new insights to the dermatology network and reflects our commitment to improving the quality of care for others with psoriasis,” said Emmanuel Caeymaex, executive vice president of Immunology Solutions and director of UCB USA.
Interim knowledge of the BE BRIGHT examination presented at the EADV showed that patients treated with bimekizumab achieved sustained degrees of skin clearance (PASI 90 and PASI hundred) for up to two years at a continuous maintenance dose, and that bimekizumab was sometimes well tolerated, with no new protective signs identified. 1,2,3 Switching to bimekizumab after 24 weeks of treatment with adalimumab (BE SURE) resulted in a sustained increase in reaction rates. PASI 90 and PASI one hundred for up to two years. 1,4 In addition, switching to bimekizumab after 52 weeks of treatment with ustekinumab (BE VIVID) resulted in a sustained increase in PASI hundred reaction rates up to week one hundred. 2,5 Patients who switched to bimekizumab after an insufficient reaction to ustekinumab at week 52 also had PASI 100). 2